

In the Claims

*PV  
P.B  
12/10/01*  
Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing.

Please cancel claims 3-7, 9, 15, 17, 20, 30-31, 34-35, and 39 without prejudice or disclaimer.

Please amend pending claims 1, 14, and 38 as noted below.

1. (Currently amended) An isolated TgAMA-1 polypeptide molecule comprising consisting  
essentially of an antigenic fragment of the polypeptide sequence set forth as amino acids 23-456 of SEQ ID NO:1.
2. (Original) A fusion protein comprising the antigenic polypeptide of claim 1.

3-13. (Cancelled)

*3*  
14. (Currently Amended) A vaccine composition comprising the isolated TgAMA-1 polypeptide of claim 1 and ~~an adjuvant~~ a *Pharmaceutically acceptable carrier*.

15-22. (Cancelled)

*6*  
23. (Original) A TgAMA-1 binding polypeptide that selectively binds to the isolated TgAMA-1 polypeptide of claim 1.

*7*  
24. (Original) The TgAMA-1 binding polypeptide of claim *23*, wherein the binding polypeptide is an antibody or antigen-binding fragment of an antibody.

8 25. (Original) The TgAMA-1 binding polypeptide of claim 24, wherein the antibody or antigen-binding fragment specifically binds to a region comprising about 12 or more cysteine residues of the isolated polypeptide of claim 1.

9 26. (Original) The TgAMA-1 binding polypeptide of claim 23, wherein the binding polypeptide blocks entry of Toxoplasma parasite into a cell.

27-37. (Cancelled)

4 38. (Previously Presented) The ~~vaccine~~ composition of claim 14, wherein the ~~vaccine~~ composition is a proteosome ~~vaccine~~.

39. (Cancelled)

5 40. The composition of claim 14, wherein the composition includes an adjuvant.